(I-BusinessNews.Com, December 17, 2018 ) The global metabolic disorder market, one of the segments of healthcare services industry. During the historic period it grew at a compound annual growth rate (CAGR) of around 12%. This was mainly due to growing diabetic population worldwide, and increasing academia-industry collaborations to develop new drugs for treatment of metabolic disorders
For the forecasted period, the metabolic disorder market size is expected to be over $124 billion by 2021, growing at a CAGR of nearly 10%. The market is expected to be driven by rapid growth in diabetic patients which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030
Find TBRC’s report on the batteries manufacturing market:
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report-2018
Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients.
Download a sample report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=277&type=smp
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
The Business Research Company
Marketing TBRC
+91 8897263534
Marketing@tbrc.info
Source: EmailWire.Com 
